' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort.
Greeve, I; Sellner, J; Lauterburg, T; Walker, U; Rösler, KM; Mattle, HP;
Acta Neurol Scand. 2007; 116(4):207-210
Originalarbeiten (Zeitschrift)


Sellner Johann


In patients with a clinically isolated syndrome (CIS), the time interval to convert to clinically definite multiple sclerosis (CDMS) is highly variable. Individual and geographical prognostic factors remain to be determined. Whether anti-myelin antibodies may predict the risk of conversion to CDMS in Swiss CIS patients of the canton Berne was the subject of the study.
Anti-myelin oligodendrocyte glycoprotein and anti-myelin basic protein antibodies were determined prospectively in patients admitted to our department.
After a mean follow-up of 12 months, none of nine antibody-negative, but 22 of 30 antibody-positive patients had progressed to CDMS. Beta-Interferon treatment delayed the time to conversion from a mean of 7.4 to 10.9 months.
In a Swiss cohort, antibody-negative CIS patients have a favorable short-term prognosis, and antibody-positive patients benefit from early treatment.

Useful keywords (using NLM MeSH Indexing)

Adjuvants, Immunologic/therapeutic use



Cohort Studies



Interferon beta-1a

Interferon-beta/therapeutic use


Middle Aged

Multiple Sclerosis/blood*

Multiple Sclerosis/drug therapy

Multiple Sclerosis/etiology*

Myelin Basic Protein

Myelin Proteins

Myelin-Associated Glycoprotein/immunology*

Myelin-Oligodendrocyte Glycoprotein

Nerve Tissue Proteins/immunology*

Risk Factors


Transcription Factors/immunology*

Treatment Outcome

Find related publications in this database (Keywords)

clinically isolated syndrome
anti-myelin aligodendracyte glycoprotein
anti-myelin basic protein
Swiss cohort